KZ
Kazia Therapeutics Ltd ADR
KZIA · NASDAQ
$9.44 -12.51% (-$1.35)
1M -20.81%
Market Cap $24.2M
P/E Ratio -
Div. Yield -
ROE 340.84%
Bulios Fair Price
$5.74
39.2% downside
Current Price
$9.44
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KZIA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 576.87x
EV/FFO N/A
P/E N/A
Growth
100 /100
Growing Rev. growth 61.34%
Book val. growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 33,850.00%
Gross margin 100.00%
FCF margin 31,614.30%
Quality
40 /100
Average ROA 341.56%
ROIC 172.61%
Asset turnover 0.01x
Debt
0 /100
High Current ratio 0.35x
Net debt/EBITDA N/A
Debt/Equity N/A
Stability
19 /100
Unstable EPS volatility 33.25%
Beta 2.15x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KZIA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Friend
Employees
6
Headquarters
Sydney
Upcoming events
02 MAR
Earnings
Upcoming earnings report